Forget GameStop, this stock is a perfect short-squeeze candidate

GameStop and Short Squeeze Trends - GameStop (NYSE: GME) has been a hot topic due to renewed trading activity from Roaring Kitty, drawing attention away from other potential short squeeze targets [1] - Olema Pharmaceuticals (NASDAQ: OLMA) has seen a significant surge, with its stock price rising by 52.56% in the last five trading sessions, from $9.17 to$13.95 [1] Olema Pharmaceuticals' Stock Performance - Olema Pharmaceuticals' stock surge is not based on speculation but has viable reasons for success [2] - The company's stock has experienced sustainable gains, particularly in recent sessions [1] Pfizer's Breakthrough and Its Impact on Olema - Pfizer's (NYSE: PFE) drug PF-07248144, targeting histone lysine acetyltransferases (KATs), showed promising results in a Phase 1 trial, with a 'tolerable safety profile and durable antitumor activity' when combined with fulvestrant for HER2-negative breast cancer patients [3] - Olema's KAT6 inhibitor, OP-3136, is in preclinical development and works similarly to Pfizer's drug, potentially benefiting from Pfizer's breakthrough [3] - This development could significantly impact cancer treatment and bring impressive gains to Olema's stock [3] Analyst Opinions on Olema Pharmaceuticals - Oppenheimer analyst Matthew Biegler described Pfizer's findings as 'the most exciting Phase 1 results' and has an 'outperform' rating on Olema with a $21 per share target [4][5] - Biegler noted that Olema is the only other publicly traded biotech company studying KAT-6 and that its potential cancer therapy, OP-3136, 'looks better' [5] - Jefferies analyst Michael Yee highlighted KAT6 as a novel cancer target and expects interest in Olema to increase, with a 'buy' rating and a$30 target on OLMA [5]